Abstract
Background
The guideline on the management of anticoagulants and antiplatelet agents for endoscopic procedures was established by the Japan Gastroenterological Endoscopy Society in 2005. However, the degree to which this guideline has reached prescribing doctors in other fields has not, so far, been evaluated.
Method
Medical records of all patients who underwent scheduled endoscopy from January 2008 to December 2008 in the Department of Gastroenterology at the University of Tokyo were investigated retrospectively.
Results
Among 8921 patients underwent scheduled endoscopy, 1383 patients (15.5%) were receiving anticoagulants or antiplatelet agents. 324 patients (23.4%) were receiving warfarin as an anticoagulant. The most common antiplatelet agent was aspirin in 884 patients (63.9%), followed by ticlopidine in 150 patients (10.8%). Most patients taking warfarin alone (51.6%) or a combination of aspirin and ticlopidine (68.4%) underwent endoscopy without cessation. In contrast, most patients taking aspirin alone (46.0%) or ticlopidine alone (56.3%) underwent endoscopy after a cessation period of 6–7 days, indicating the low permeation of the cessation policy recommended in the guideline. Among 556 patients underwent endoscopy without a cessation period, 41 patients (7.4%) underwent invasive procedures including endoscopic mucosal resection. No bleeding complications were observed in patients who underwent invasive procedures without a cessation period.
Conclusion
We revealed the low permeation of the guideline to prescribing doctors. Cessation before endoscopy to avoid bleeding complications can be dispensable.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy—I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81–106.
Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1–13.
Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502.
Shinohara Y, Gotoh F, Tohgi H, et al. Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. Subgroup analysis of the cilostazol stroke prevention study. Cerebrovasc Dis. 2008;26:63–70.
Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ. 1995;310:827–30.
Sorensen HT, Mellemkjaer L, Blot WJ, et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol. 2000;95:2218–24.
Hallas J, Dall M, Andries A, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ. 2006;333:726.
Taha AS, Angerson WJ, Knill-Jones RP, Blatchford O. Upper gastrointestinal mucosal abnormalities and blood loss complicating low-dose aspirin and antithrombotic therapy. Aliment Pharmacol Ther. 2006;23:489–95.
Aronow HD, Steinhubl SR, Brennan DM, Berger PB, Topol EJ. Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J. 2009;157:369–74.
Ogoshi K, Kaneko E, Tada M, et al. The management of anticoagulation and antiplatelet therapy for endoscopic procedures. Gastroenterol Endosc. 2005;47:2691–5.
Eisen GM, Baron TH, Dominitz JA, et al. Guideline on the management of anticoagulation and antiplatelet therapy for endoscopic procedures. Gastrointest Endosc. 2002;55:775–9.
Zuckerman MJ, Hirota WK, Adler DG, et al. ASGE guideline: the management of low-molecular-weight heparin and nonaspirin antiplatelet agents for endoscopic procedures. Gastrointest Endosc. 2005;61:189–94.
Fujishiro M, Oda I, Yamamoto Y, et al. Multi-center survey regarding the management of anticoagulation and antiplatelet therapy for endoscopic procedures in Japan. J Gastroenterol Hepatol. 2009;24:214–8.
Napoleon B, Boneu B, Maillard L, et al. Guidelines of the French society for digestive endoscopy (SFED). Endoscopy. 2006;38:632–8.
Japanese Circulation Society. Guidelines for management of anticoagulant and antiplatelet therapy in cardiovascular disease (JCS 2004) (in Japanese). Circ J. 2004;68:1153–219.
Komatsu T, Tamai Y, Takami H, Yamagata K, Fukuda S, Munakata A. Study for determination of the optimal cessation period of therapy with anti-platelet agents prior to invasive endoscopic procedures. J Gastroenterol. 2005;40:698–707.
Lee SY, Tang SJ, Rockey DC, et al. Managing anticoagulation and antiplatelet medications in GI endoscopy: a survey comparing the east and the west. Gastrointest Endosc. 2008;67:1076–81.
Ido K, Togashi K, Yamamoto H, Satoh K. How antiplatelets and anticoagulants should be managed in endoscopic treatment. Gastroenterol Endosc. 2004;46:2079–85. (in Japanese with English abstract).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ono, S., Fujishiro, M., Hirano, K. et al. Retrospective analysis on the management of anticoagulants and antiplatelet agents for scheduled endoscopy. J Gastroenterol 44, 1185–1189 (2009). https://doi.org/10.1007/s00535-009-0127-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00535-009-0127-6